| Followers | 2543 |
| Posts | 250731 |
| Boards Moderated | 34 |
| Alias Born | 05/06/2014 |
Thursday, March 23, 2017 1:24:26 PM
$PMCB Pharmacyte Biotech Inc (OTCMKTS:PMCB) Holds A Shareholder Call As It Promises To Answer Most Of The Questions By Shareholders And Analysts PMCB
Pharmacyte Biotech Inc (OTCMKTS:PMCB), one of the top clinical stage biotechnology companies that has done much towards developing targeted treatments for diabetes and cancer has been hitting headlines lately for the positive steps it has been making towards helping patients around the globe obtain high quality forms of medication.
It has made great use of its signature live-cell encapsulation technology, Cell-in-a-Box® in the development of top-notch solutions for cancer and diabetes some of which have been put under thorough tests to establish their effectiveness towards facing out the life-threatening complications.
This day comes with the freshest news regarding the company where Kenneth L. Waggoner who happens to be Chief Executive Officer for the company is spearheading a shareholder conference call in a short while. The top official went ahead to comment on the upcoming shareholder conference where he made it clear that the company would be experiencing a positive pre-IND meeting with the United State’s FDA.
He observed and referred to it as a landmark moment for the high end biotechnology company stating that it had indeed made tremendous steps in terms of economic progress. Asides from this, the top provider had also obtained great advice as well as guidance in regards to the objective of filing its IND.
At the moment, the company boasts of having in place a clear path forward and as a matter of fact, the upcoming shareholder call will clear out matters for shareholders, analysts and the general public. The management looks forward to unveiling the latest information to shareholders as well as analysts regarding the upcoming clinical trial.
The company will be subjected to answering a number of written questions by the Food and Drug Administration which as a matter of fact it intends to respond to. Shareholders as well as analysts who might have questions are advised to post them in the company’s website and they will be answered in the best ways possible. Mr. Waggoner has made the promise to respond to a many questions as possible but of course that will be within the provided time frame.
http://www.mmjobserver.com/pharmacyte-biotech-inc-otcmktspmcb-holds-a-shareholder-call-as-it-promises-to-answer-most-of-the-questions-by-shareholders-and-analysts/9372/
Pharmacyte Biotech Inc (OTCMKTS:PMCB), one of the top clinical stage biotechnology companies that has done much towards developing targeted treatments for diabetes and cancer has been hitting headlines lately for the positive steps it has been making towards helping patients around the globe obtain high quality forms of medication.
It has made great use of its signature live-cell encapsulation technology, Cell-in-a-Box® in the development of top-notch solutions for cancer and diabetes some of which have been put under thorough tests to establish their effectiveness towards facing out the life-threatening complications.
This day comes with the freshest news regarding the company where Kenneth L. Waggoner who happens to be Chief Executive Officer for the company is spearheading a shareholder conference call in a short while. The top official went ahead to comment on the upcoming shareholder conference where he made it clear that the company would be experiencing a positive pre-IND meeting with the United State’s FDA.
He observed and referred to it as a landmark moment for the high end biotechnology company stating that it had indeed made tremendous steps in terms of economic progress. Asides from this, the top provider had also obtained great advice as well as guidance in regards to the objective of filing its IND.
At the moment, the company boasts of having in place a clear path forward and as a matter of fact, the upcoming shareholder call will clear out matters for shareholders, analysts and the general public. The management looks forward to unveiling the latest information to shareholders as well as analysts regarding the upcoming clinical trial.
The company will be subjected to answering a number of written questions by the Food and Drug Administration which as a matter of fact it intends to respond to. Shareholders as well as analysts who might have questions are advised to post them in the company’s website and they will be answered in the best ways possible. Mr. Waggoner has made the promise to respond to a many questions as possible but of course that will be within the provided time frame.
http://www.mmjobserver.com/pharmacyte-biotech-inc-otcmktspmcb-holds-a-shareholder-call-as-it-promises-to-answer-most-of-the-questions-by-shareholders-and-analysts/9372/
investorshub.advfn.com/$Pistol-Pete$-$Mick$-&-Friends-Stock-Picks-29568/
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
